Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | PGK1 | P00558 | 6/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | GLP1R | P43220 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440326 | 0.85 | ALDH1A1 (0.45) | KDM4EGALR3PDE10ABTKRAB9A | |
| SCHEMBL31320118 | 0.79 | ABL1 (0.41) | EGFR | |
| SCHEMBL27851723 | 0.78 | KDM4E (0.41) | KDM4EMAP4K4PGK1GALR3SIRT2 | |
| SCHEMBL1440229 | 0.78 | PDPK1 (0.37) | MAP4K4PGK1GALR3 | |
| SCHEMBL4060781 | 0.77 | GALR3 (0.56) | KDM4EMAP4K4PGK1GALR3SIRT2 | |
| SCHEMBL29253823 | 0.77 | KDM4E (0.37) | KDM4EMAP4K4PGK1GALR3GLP1R | |
| SCHEMBL23396651 | 0.75 | MAPT (0.31) | KDM4EGALR3RAB9A | |
| SCHEMBL8243683 | 0.74 | PGK1 (0.41) | KDM4EMAP4K4PGK1GALR3 | |
| SCHEMBL28505552 | 0.73 | SMN1; SMN2 (0.40) | KDM4EMAP4K4GLP1RPDE10ACD38 | |
| SCHEMBL23396724 | 0.73 | TLR8 (0.37) | KDM4EGLP1RRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246988-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-07-25 | — | — | US | disclosed |
| CN-112300172-B | Bruton tyrosine kinase inhibitors | 比奥根MA公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2023-02-16 | — | — | US | disclosed |
| CN-112300172-A | Bruton's tyrosine kinase inhibitors | 比奥根MA公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| CN-107011330-B | Bruton's tyrosine kinase inhibitors | 比奥根MA公司 | 2020-07-03 | — | — | CN | disclosed |
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3461824-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Biogen MA Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-2473049-B1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
| US-9790229-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9249146-B2 | Bruton'S tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-10-16 | — | — | US | disclosed |
| US-8785440-B2 | Bruton's tyrosine kinase inhibitors | BIOGEN IDEC MA, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2473049-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Biogen Idec MA Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011029046-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246988-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | KDM4E 1208/4885MAP4K4 592/4885PGK1 1657/4885 |
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | KDM4E 1208/4885MAP4K4 592/4885PGK1 1657/4885 |
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | KDM4E 1208/4885MAP4K4 592/4885PGK1 1657/4885 |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | KDM4E 1208/4885MAP4K4 592/4885PGK1 1657/4885 |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | KDM4E 1208/4885MAP4K4 592/4885PGK1 1657/4885 |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | KDM4E 1208/4885MAP4K4 592/4885PGK1 1657/4885 |
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | KDM4E 1208/4885MAP4K4 592/4885PGK1 1657/4885 |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | KDM4E 1208/4885MAP4K4 592/4885PGK1 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.